New T cell–based immunotherapy shows promise for lethal stem cell transplant complication
New T cell–based immunotherapy shows promise for lethal stem cell transplant complication
Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker
Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial
How to decide the treatment of CLL in 2015
ecancermedicalscience editor's choice for March 2015
Expert insight: Radiation oncology with the Scientific Director of the IEO
BRAF 'behind the scenes' in melanoma: A scientific story of discovery
Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice
Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions
Targeting CDK pathways in cancer treatment
DNA repair inhibitors to overcome drug resistance
Refining the role of PARP inhibitors in targeted anticancer therapy